FY2024 EPS Estimates for 2seventy bio Decreased by Analyst

2seventy bio, Inc. (NASDAQ:TSVT) – Leerink Partnrs dropped their FY2024 earnings per share (EPS) estimates for 2seventy bio in a research report issued to clients and investors on Wednesday, December 4th. Leerink Partnrs analyst D. Graybosch now expects that the company will earn ($1.45) per share for the year, down from their previous forecast of ($1.13). The consensus estimate for 2seventy bio’s current full-year earnings is ($0.76) per share. Leerink Partnrs also issued estimates for 2seventy bio’s Q4 2024 earnings at ($0.17) EPS, Q1 2025 earnings at ($0.04) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at $0.01 EPS, Q4 2025 earnings at $0.00 EPS, FY2025 earnings at ($0.09) EPS, FY2026 earnings at $0.12 EPS, FY2027 earnings at $0.53 EPS and FY2028 earnings at $0.66 EPS.

2seventy bio Price Performance

NASDAQ:TSVT opened at $3.53 on Friday. The firm’s 50-day moving average price is $4.39 and its 200-day moving average price is $4.38. The company has a market capitalization of $182.11 million, a PE ratio of -1.90 and a beta of 1.69. 2seventy bio has a 1-year low of $2.29 and a 1-year high of $6.40.

Hedge Funds Weigh In On 2seventy bio

Several large investors have recently made changes to their positions in TSVT. Geode Capital Management LLC raised its position in shares of 2seventy bio by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock worth $5,553,000 after purchasing an additional 13,144 shares during the last quarter. XTX Topco Ltd increased its stake in 2seventy bio by 61.1% during the 3rd quarter. XTX Topco Ltd now owns 24,416 shares of the company’s stock valued at $115,000 after purchasing an additional 9,257 shares in the last quarter. Wellington Management Group LLP raised its holdings in 2seventy bio by 9.0% in the third quarter. Wellington Management Group LLP now owns 262,040 shares of the company’s stock worth $1,237,000 after buying an additional 21,673 shares during the last quarter. Western Standard LLC bought a new position in shares of 2seventy bio in the third quarter worth approximately $1,350,000. Finally, State Street Corp grew its holdings in shares of 2seventy bio by 1.5% during the third quarter. State Street Corp now owns 1,058,773 shares of the company’s stock valued at $4,997,000 after buying an additional 15,638 shares during the last quarter. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.